PanCareSurPass Project HL7 FHIR Implementation Guide
1.0.0 - release 150

PanCareSurPass Project HL7 FHIR Implementation Guide, published by PanCareSurPass Project. This guide is not an authorized publication; it is the continuous build for version 1.0.0 built by the FHIR (HL7® FHIR® Standard) CI Build. This version is based on the current content of https://github.com/hl7-eu/pcsp/ and changes regularly. See the Directory of published versions

## : PCSP Conditions at risk - XML Representation

Active as of 2025-10-16

Raw xml | Download

    <CodeSystem xmlns="http://hl7.org/fhir">
      <id value="cs-riskcondition-eu-pcsp"/>
      <text>
        <status value="generated"/>
        <div xmlns="http://www.w3.org/1999/xhtml"><p class="res-header-id"><b>Generated Narrative: CodeSystem cs-riskcondition-eu-pcsp</b></p><a name="cs-riskcondition-eu-pcsp"> </a><a name="hccs-riskcondition-eu-pcsp"> </a><p>This case-sensitive code system <code>http://hl7.eu/fhir/ig/pcsp/CodeSystem/cs-riskcondition-eu-pcsp</code> defines the following codes:</p><table class="codes"><tr><td style="white-space:nowrap"><b>Code</b></td><td><b>Display</b></td><td><b>Definition</b></td></tr><tr><td style="white-space:nowrap">1<a name="cs-riskcondition-eu-pcsp-1"> </a></td><td>Subsequent thyroid cancer</td><td>Subsequent thyroid cancer</td></tr><tr><td style="white-space:nowrap">2<a name="cs-riskcondition-eu-pcsp-2"> </a></td><td>Subsequent breast cancer</td><td>Subsequent breast cancer</td></tr><tr><td style="white-space:nowrap">3<a name="cs-riskcondition-eu-pcsp-3"> </a></td><td>Cardiac problems (Cardiomyopathy and/or Valvular disease and/or Cardiac ischemia)</td><td>Cardiac problems (Cardiomyopathy and/or Valvular disease and/or Cardiac ischemia)</td></tr><tr><td style="white-space:nowrap">4<a name="cs-riskcondition-eu-pcsp-4"> </a></td><td>Impaired fertility Impaired spermatogenesis</td><td>Impaired fertility Impaired spermatogenesis</td></tr><tr><td style="white-space:nowrap">5<a name="cs-riskcondition-eu-pcsp-5"> </a></td><td>Testosterone deficiency</td><td>Testosterone deficiency</td></tr><tr><td style="white-space:nowrap">6<a name="cs-riskcondition-eu-pcsp-6"> </a></td><td>Physical sexual dysfunction</td><td>Physical sexual dysfunction</td></tr><tr><td style="white-space:nowrap">7<a name="cs-riskcondition-eu-pcsp-7"> </a></td><td>Premature ovarian insufficiency</td><td>Premature ovarian insufficiency</td></tr><tr><td style="white-space:nowrap">8<a name="cs-riskcondition-eu-pcsp-8"> </a></td><td>Ear problems</td><td>Ear problems</td></tr><tr><td style="white-space:nowrap">9<a name="cs-riskcondition-eu-pcsp-9"> </a></td><td>Impaired glucose metabolism and diabetes melitus</td><td>Impaired glucose metabolism and diabetes melitus</td></tr><tr><td style="white-space:nowrap">10<a name="cs-riskcondition-eu-pcsp-10"> </a></td><td>Dyslipidemia</td><td>Dyslipidemia</td></tr><tr><td style="white-space:nowrap">11<a name="cs-riskcondition-eu-pcsp-11"> </a></td><td>Overweight and obesity</td><td>Overweight and obesity</td></tr><tr><td style="white-space:nowrap">12<a name="cs-riskcondition-eu-pcsp-12"> </a></td><td>Hypertension</td><td>Hypertension</td></tr><tr><td style="white-space:nowrap">13<a name="cs-riskcondition-eu-pcsp-13"> </a></td><td>Reduced bone mineral density</td><td>Reduced bone mineral density</td></tr><tr><td style="white-space:nowrap">14<a name="cs-riskcondition-eu-pcsp-14"> </a></td><td>Osteonecrosis</td><td>Osteonecrosis</td></tr><tr><td style="white-space:nowrap">15<a name="cs-riskcondition-eu-pcsp-15"> </a></td><td>Hypothalamic-pituitary (HP) axis problems (High risk) Growth hormone deficiency (GHD) TSH deficiency (TSHD) LH/FSH deficiency (LH/FSHD) ACTH deficiency (ACTHD)</td><td>Hypothalamic-pituitary (HP) axis problems (High risk) Growth hormone deficiency (GHD) TSH deficiency (TSHD) LH/FSH deficiency (LH/FSHD) ACTH deficiency (ACTHD)</td></tr><tr><td style="white-space:nowrap">16<a name="cs-riskcondition-eu-pcsp-16"> </a></td><td>Hypothalamic-pituitary (HP) axis problems (Standard risk) Growth hormone deficiency (GHD) TSH deficiency (TSHD) LH/FSH deficiency (LH/FSHD) ACTH deficiency (ACTHD)</td><td>Hypothalamic-pituitary (HP) axis problems (Standard risk) Growth hormone deficiency (GHD) TSH deficiency (TSHD) LH/FSH deficiency (LH/FSHD) ACTH deficiency (ACTHD)</td></tr><tr><td style="white-space:nowrap">17<a name="cs-riskcondition-eu-pcsp-17"> </a></td><td>Central precocious puberty (CPP) For girls with age below 8 years</td><td>Central precocious puberty (CPP) For girls with age below 8 years</td></tr><tr><td style="white-space:nowrap">18<a name="cs-riskcondition-eu-pcsp-18"> </a></td><td>Central precocious puberty (CPP) For boys with age below 9 yearss</td><td>Central precocious puberty (CPP) For boys with age below 9 yearss</td></tr><tr><td style="white-space:nowrap">19<a name="cs-riskcondition-eu-pcsp-19"> </a></td><td>Thyroid function problems</td><td>Thyroid function problems</td></tr><tr><td style="white-space:nowrap">20<a name="cs-riskcondition-eu-pcsp-20"> </a></td><td>Cerebrovascular problem</td><td>Cerebrovascular problem</td></tr><tr><td style="white-space:nowrap">21<a name="cs-riskcondition-eu-pcsp-21"> </a></td><td>Neurocognitive problems</td><td>Neurocognitive problems</td></tr><tr><td style="white-space:nowrap">22<a name="cs-riskcondition-eu-pcsp-22"> </a></td><td>Peripheral neuropathy</td><td>Peripheral neuropathy</td></tr><tr><td style="white-space:nowrap">23<a name="cs-riskcondition-eu-pcsp-23"> </a></td><td>Cataract</td><td>Cataract</td></tr><tr><td style="white-space:nowrap">24<a name="cs-riskcondition-eu-pcsp-24"> </a></td><td>Eye problems</td><td>Eye problems</td></tr><tr><td style="white-space:nowrap">25<a name="cs-riskcondition-eu-pcsp-25"> </a></td><td>Craniofacial growth problems</td><td>Craniofacial growth problems</td></tr><tr><td style="white-space:nowrap">26<a name="cs-riskcondition-eu-pcsp-26"> </a></td><td>Spine scoliosis and kyphosis</td><td>Spine scoliosis and kyphosis</td></tr><tr><td style="white-space:nowrap">27<a name="cs-riskcondition-eu-pcsp-27"> </a></td><td>Lower urinary tract problems</td><td>Lower urinary tract problems</td></tr><tr><td style="white-space:nowrap">28<a name="cs-riskcondition-eu-pcsp-28"> </a></td><td>Obstetric problems</td><td>Obstetric problems</td></tr><tr><td style="white-space:nowrap">29<a name="cs-riskcondition-eu-pcsp-29"> </a></td><td>Dental and oral problems</td><td>Dental and oral problems</td></tr><tr><td style="white-space:nowrap">30<a name="cs-riskcondition-eu-pcsp-30"> </a></td><td>Gastro-intestinal problems</td><td>Gastro-intestinal problems</td></tr><tr><td style="white-space:nowrap">31<a name="cs-riskcondition-eu-pcsp-31"> </a></td><td>Arrhythmia</td><td>Arrhythmia</td></tr><tr><td style="white-space:nowrap">32<a name="cs-riskcondition-eu-pcsp-32"> </a></td><td>Pulmonary problems</td><td>Pulmonary problems</td></tr><tr><td style="white-space:nowrap">33<a name="cs-riskcondition-eu-pcsp-33"> </a></td><td>Renal problems (Glomerular dysfunction - Tubular dysfunction)</td><td>Renal problems (Glomerular dysfunction - Tubular dysfunction)</td></tr><tr><td style="white-space:nowrap">34<a name="cs-riskcondition-eu-pcsp-34"> </a></td><td>Liver problems</td><td>Liver problems</td></tr><tr><td style="white-space:nowrap">35<a name="cs-riskcondition-eu-pcsp-35"> </a></td><td>Iron overload</td><td>Iron overload</td></tr><tr><td style="white-space:nowrap">36<a name="cs-riskcondition-eu-pcsp-36"> </a></td><td>Spleen problems</td><td>Spleen problems</td></tr><tr><td style="white-space:nowrap">37<a name="cs-riskcondition-eu-pcsp-37"> </a></td><td>Tumor predisposition</td><td>Tumor predisposition</td></tr><tr><td style="white-space:nowrap">38<a name="cs-riskcondition-eu-pcsp-38"> </a></td><td>Subsequent melanoma and non-melanoma skin cancer</td><td>Subsequent melanoma and non-melanoma skin cancer</td></tr><tr><td style="white-space:nowrap">39<a name="cs-riskcondition-eu-pcsp-39"> </a></td><td>Subsequent colorectal cancer</td><td>Subsequent colorectal cancer</td></tr><tr><td style="white-space:nowrap">40<a name="cs-riskcondition-eu-pcsp-40"> </a></td><td>Subsequent Oral Cancer</td><td>Subsequent Oral Cancer</td></tr><tr><td style="white-space:nowrap">41<a name="cs-riskcondition-eu-pcsp-41"> </a></td><td>Subsequent acute myeloid leukaemia or myelodysplasia</td><td>Subsequent acute myeloid leukaemia or myelodysplasia</td></tr><tr><td style="white-space:nowrap">42<a name="cs-riskcondition-eu-pcsp-42"> </a></td><td>Subsequent bladder cancer</td><td>Subsequent bladder cancer</td></tr><tr><td style="white-space:nowrap">43<a name="cs-riskcondition-eu-pcsp-43"> </a></td><td>Subsequent Bone Cancer</td><td>Subsequent Bone Cancer</td></tr><tr><td style="white-space:nowrap">44<a name="cs-riskcondition-eu-pcsp-44"> </a></td><td>Subsequent lung cancer</td><td>Subsequent lung cancer</td></tr><tr><td style="white-space:nowrap">45<a name="cs-riskcondition-eu-pcsp-45"> </a></td><td>Subsequent CNS neoplasms</td><td>Subsequent CNS neoplasms</td></tr><tr><td style="white-space:nowrap">46<a name="cs-riskcondition-eu-pcsp-46"> </a></td><td>Cardiac problems (Cardiomyopathy and/or Valvular disease and/or Cardiac ischemia)</td><td>Cardiac problems (Cardiomyopathy and/or Valvular disease and/or Cardiac ischemia)</td></tr><tr><td style="white-space:nowrap">47<a name="cs-riskcondition-eu-pcsp-47"> </a></td><td>Renal problems (Tubular dysfunction)</td><td>Renal problems (Tubular dysfunction)</td></tr></table></div>
      </text>
      <url
           value="http://hl7.eu/fhir/ig/pcsp/CodeSystem/cs-riskcondition-eu-pcsp"/>
      <version value="1.0.0"/>
      <name value="CsRiskConditionPcsp"/>
      <title value="PCSP Conditions at risk"/>
      <status value="active"/>
      <experimental value="false"/>
      <date value="2025-10-16T12:02:24+00:00"/>
      <publisher value="PanCareSurPass Project"/>
      <contact>
        <name value="PanCareSurPass Project"/>
        <telecom>
          <system value="url"/>
          <value value="https://www.pancaresurpass.eu/"/>
        </telecom>
      </contact>
      <contact>
        <name value="PanCareSurPass Project"/>
        <telecom>
          <system value="url"/>
          <value value="https://www.pancaresurpass.eu/"/>
        </telecom>
      </contact>
      <description value="Condition at risk proposed by the PCSP algorithm"/>
      <jurisdiction>
        <coding>
          <system value="http://unstats.un.org/unsd/methods/m49/m49.htm"/>
          <code value="150"/>
          <display value="Europe"/>
        </coding>
      </jurisdiction>
      <caseSensitive value="true"/>
      <content value="complete"/>
      <count value="47"/>
      <concept>
        <code value="1"/>
        <display value="Subsequent thyroid cancer"/>
        <definition value="Subsequent thyroid cancer"/>
      </concept>
      <concept>
        <code value="2"/>
        <display value="Subsequent breast cancer"/>
        <definition value="Subsequent breast cancer"/>
      </concept>
      <concept>
        <code value="3"/>
        <display
                 value="Cardiac problems (Cardiomyopathy and/or Valvular disease and/or Cardiac ischemia)"/>
        <definition
                    value="Cardiac problems (Cardiomyopathy and/or Valvular disease and/or Cardiac ischemia)"/>
      </concept>
      <concept>
        <code value="4"/>
        <display value="Impaired fertility Impaired spermatogenesis"/>
        <definition value="Impaired fertility Impaired spermatogenesis"/>
      </concept>
      <concept>
        <code value="5"/>
        <display value="Testosterone deficiency"/>
        <definition value="Testosterone deficiency"/>
      </concept>
      <concept>
        <code value="6"/>
        <display value="Physical sexual dysfunction"/>
        <definition value="Physical sexual dysfunction"/>
      </concept>
      <concept>
        <code value="7"/>
        <display value="Premature ovarian insufficiency"/>
        <definition value="Premature ovarian insufficiency"/>
      </concept>
      <concept>
        <code value="8"/>
        <display value="Ear problems"/>
        <definition value="Ear problems"/>
      </concept>
      <concept>
        <code value="9"/>
        <display value="Impaired glucose metabolism and diabetes melitus"/>
        <definition value="Impaired glucose metabolism and diabetes melitus"/>
      </concept>
      <concept>
        <code value="10"/>
        <display value="Dyslipidemia"/>
        <definition value="Dyslipidemia"/>
      </concept>
      <concept>
        <code value="11"/>
        <display value="Overweight and obesity"/>
        <definition value="Overweight and obesity"/>
      </concept>
      <concept>
        <code value="12"/>
        <display value="Hypertension"/>
        <definition value="Hypertension"/>
      </concept>
      <concept>
        <code value="13"/>
        <display value="Reduced bone mineral density"/>
        <definition value="Reduced bone mineral density"/>
      </concept>
      <concept>
        <code value="14"/>
        <display value="Osteonecrosis"/>
        <definition value="Osteonecrosis"/>
      </concept>
      <concept>
        <code value="15"/>
        <display
                 value="Hypothalamic-pituitary (HP) axis problems (High risk) Growth hormone deficiency (GHD) TSH deficiency (TSHD) LH/FSH deficiency (LH/FSHD) ACTH deficiency (ACTHD)"/>
        <definition
                    value="Hypothalamic-pituitary (HP) axis problems (High risk) Growth hormone deficiency (GHD) TSH deficiency (TSHD) LH/FSH deficiency (LH/FSHD) ACTH deficiency (ACTHD)"/>
      </concept>
      <concept>
        <code value="16"/>
        <display
                 value="Hypothalamic-pituitary (HP) axis problems (Standard risk) Growth hormone deficiency (GHD) TSH deficiency (TSHD) LH/FSH deficiency (LH/FSHD) ACTH deficiency (ACTHD)"/>
        <definition
                    value="Hypothalamic-pituitary (HP) axis problems (Standard risk) Growth hormone deficiency (GHD) TSH deficiency (TSHD) LH/FSH deficiency (LH/FSHD) ACTH deficiency (ACTHD)"/>
      </concept>
      <concept>
        <code value="17"/>
        <display
                 value="Central precocious puberty (CPP) For girls with age below 8 years"/>
        <definition
                    value="Central precocious puberty (CPP) For girls with age below 8 years"/>
      </concept>
      <concept>
        <code value="18"/>
        <display
                 value="Central precocious puberty (CPP) For boys with age below 9 yearss"/>
        <definition
                    value="Central precocious puberty (CPP) For boys with age below 9 yearss"/>
      </concept>
      <concept>
        <code value="19"/>
        <display value="Thyroid function problems"/>
        <definition value="Thyroid function problems"/>
      </concept>
      <concept>
        <code value="20"/>
        <display value="Cerebrovascular problem"/>
        <definition value="Cerebrovascular problem"/>
      </concept>
      <concept>
        <code value="21"/>
        <display value="Neurocognitive problems"/>
        <definition value="Neurocognitive problems"/>
      </concept>
      <concept>
        <code value="22"/>
        <display value="Peripheral neuropathy"/>
        <definition value="Peripheral neuropathy"/>
      </concept>
      <concept>
        <code value="23"/>
        <display value="Cataract"/>
        <definition value="Cataract"/>
      </concept>
      <concept>
        <code value="24"/>
        <display value="Eye problems"/>
        <definition value="Eye problems"/>
      </concept>
      <concept>
        <code value="25"/>
        <display value="Craniofacial growth problems"/>
        <definition value="Craniofacial growth problems"/>
      </concept>
      <concept>
        <code value="26"/>
        <display value="Spine scoliosis and kyphosis"/>
        <definition value="Spine scoliosis and kyphosis"/>
      </concept>
      <concept>
        <code value="27"/>
        <display value="Lower urinary tract problems"/>
        <definition value="Lower urinary tract problems"/>
      </concept>
      <concept>
        <code value="28"/>
        <display value="Obstetric problems"/>
        <definition value="Obstetric problems"/>
      </concept>
      <concept>
        <code value="29"/>
        <display value="Dental and oral problems"/>
        <definition value="Dental and oral problems"/>
      </concept>
      <concept>
        <code value="30"/>
        <display value="Gastro-intestinal problems"/>
        <definition value="Gastro-intestinal problems"/>
      </concept>
      <concept>
        <code value="31"/>
        <display value="Arrhythmia"/>
        <definition value="Arrhythmia"/>
      </concept>
      <concept>
        <code value="32"/>
        <display value="Pulmonary problems"/>
        <definition value="Pulmonary problems"/>
      </concept>
      <concept>
        <code value="33"/>
        <display
                 value="Renal problems (Glomerular dysfunction - Tubular dysfunction)"/>
        <definition
                    value="Renal problems (Glomerular dysfunction - Tubular dysfunction)"/>
      </concept>
      <concept>
        <code value="34"/>
        <display value="Liver problems"/>
        <definition value="Liver problems"/>
      </concept>
      <concept>
        <code value="35"/>
        <display value="Iron overload"/>
        <definition value="Iron overload"/>
      </concept>
      <concept>
        <code value="36"/>
        <display value="Spleen problems"/>
        <definition value="Spleen problems"/>
      </concept>
      <concept>
        <code value="37"/>
        <display value="Tumor predisposition"/>
        <definition value="Tumor predisposition"/>
      </concept>
      <concept>
        <code value="38"/>
        <display value="Subsequent melanoma and non-melanoma skin cancer"/>
        <definition value="Subsequent melanoma and non-melanoma skin cancer"/>
      </concept>
      <concept>
        <code value="39"/>
        <display value="Subsequent colorectal cancer"/>
        <definition value="Subsequent colorectal cancer"/>
      </concept>
      <concept>
        <code value="40"/>
        <display value="Subsequent Oral Cancer"/>
        <definition value="Subsequent Oral Cancer"/>
      </concept>
      <concept>
        <code value="41"/>
        <display value="Subsequent acute myeloid leukaemia or myelodysplasia"/>
        <definition value="Subsequent acute myeloid leukaemia or myelodysplasia"/>
      </concept>
      <concept>
        <code value="42"/>
        <display value="Subsequent bladder cancer"/>
        <definition value="Subsequent bladder cancer"/>
      </concept>
      <concept>
        <code value="43"/>
        <display value="Subsequent Bone Cancer"/>
        <definition value="Subsequent Bone Cancer"/>
      </concept>
      <concept>
        <code value="44"/>
        <display value="Subsequent lung cancer"/>
        <definition value="Subsequent lung cancer"/>
      </concept>
      <concept>
        <code value="45"/>
        <display value="Subsequent CNS neoplasms"/>
        <definition value="Subsequent CNS neoplasms"/>
      </concept>
      <concept>
        <code value="46"/>
        <display
                 value="Cardiac problems (Cardiomyopathy and/or Valvular disease and/or Cardiac ischemia)"/>
        <definition
                    value="Cardiac problems (Cardiomyopathy and/or Valvular disease and/or Cardiac ischemia)"/>
      </concept>
      <concept>
        <code value="47"/>
        <display value="Renal problems (Tubular dysfunction)"/>
        <definition value="Renal problems (Tubular dysfunction)"/>
      </concept>
    </CodeSystem>